AbbVie makes bold move in Alzheimer’s market with $1.4bn Aliada buyout—Is it a gamble?
AbbVie, the renowned American biopharmaceutical giant, is set to acquire Aliada Therapeutics for a staggering $1.4 billion. The acquisition grants AbbVie control over Aliada’s promising Alzheimer’s treatment, ALIA-1758, and the biotech’s innovative Modular Delivery (MODEL) platform, which could overcome significant barriers in treating neurological disorders, particularly Alzheimer’s disease. Key Drivers Behind the Acquisition AbbVie aims […]